Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Osteoblasts have been thought to
2024-11-13

Osteoblasts have been thought to be the major cell type that expresses RANKL (Suda et al., 1999) which is a ligand for osteoprotegerin (OPG) and which functions as a key factor for osteoclast differentiation and activation. Recently, Nakashima and his colleagues (Nakashima et al., 2011) demonstrated
-
LO is a soluble kDa enzyme
2024-11-13

5-LO is a soluble 78 kDa enzyme, composed of an α-helix-rich catalytic domain and a regulatory β-sheet-rich C2-like domain. Depending on the cell type, 5-LO may be located in the cytosol, in the nucleoplasm, or in both compartments (Werz, 2002). Upon cell stimulation by agents that elevate intracell
-
br Clinical realities br Commentary
2024-11-13

Clinical realities Commentary on uses of selective 17,20 lyase inhibitors If continued monitoring of these same parameters along with tracking of circulating ACTH in human trials confirms these new drugs are the long sought after 17,20 lyase inhibitors, then we may for the first time be able t
-
br Research perspective In vitro
2024-11-13

Research perspective In vitro and in vivo studies have demonstrated that increased LPA/ATX signaling contributes to cancer initiation and progression. Recent findings on the role of non-tumoral ATX in cancer progression and metastasis highlighted a new functional contribution for the microenviron
-
These recommendations may be useful for the future
2024-11-13

These recommendations may be useful for the future to avoid misleading reports and pairings. However, the existing literature can also hold back current research on some given orphans. Before entering into drug development or further physiological conceptual framework, these pairings should be thoro
-
The subnuclear localizations of redox regulators is also
2024-11-12

The subnuclear localizations of redox regulators is also largely unknown. The potential role of thiol reductases as transcription regulators or DNA repair molecules may suggest an association to DNA. In this way, the presence of a zinc finger domain potentially involved in protein/DNA interactions o
-
br Implementation of sacubitril valsartan into clinical
2024-11-12

Implementation of sacubitril/valsartan into clinical practice Following on from the results of PARADIGM-HF, sacubitril/valsartan was given regulatory approval for use in patients who conform to the main inclusion criteria of the trial; NYHA functional class II–IV, reduced left ventricular ejectio
-
Akt is another upstream kinase
2024-11-12

Akt is another upstream kinase known to phosphorylate AMPK Ser489 in response to high insulin levels [7], [21]. HepG2 87 7 synthesis show an increase in phosphorylation of AMPK at Ser485 when incubated with either insulin or troglitazone individually (Fig. 5A and C). Despite this concurrent increase
-
AMPK is a central regulator
2024-11-12

AMPK is a central regulator of cell growth, migration, metabolism, autophagy, and cell polarity [20], [21], [22], [23]. It is highly conserved in eukaryotes and functions as the primary sensor of intracellular adenosine nucleotides [24]. When intracellular ATP levels decrease, AMPK is activated to g
-
br Materials and methods br
2024-11-12

Materials and methods Results Discussion In the present study, we identified HBP1 as a novel substrate of AKT. This was demonstrated by in vitro phosphorylation assays and western blotting using phosphosite-specific antibodies. Three sites were identified by mass spectrometry and mutagenesi
-
According to average serum fat content
2024-11-12

According to average serum fat content of 6.9 g/L (Phillips et al., 1989) and serum dioxin level from individuals exposed to dioxins as the result of accidents in Seveso (Needham et al., 1997), Taiwan (Guo et al., 2004) and Vietnam (The Tai et al., 2011) the median serum concentration of TCDD would
-
One study has demonstrated that PUFA reduced
2024-11-12

One study has demonstrated that ω-3 PUFA reduced both cholesterol and caveolin-1 (a marker of raft), thereby displacing raft-associated signaling molecules from lipid raft [36]. Additionally, DHA treatment decreased the amount of lipid raft in the cell surface and displaced several lipid raft-associ
-
The use of a single well identified molecule to
2024-11-12

The use of a single well-identified molecule to induce AChR clusters formation can simplify complicated cell manipulation procedures and may provide a more efficient means of developing biological substitutes for functional muscle tissue restoration in vivo. Pharmacological approaches dealing with b
-
In this scenario the receptor tyrosine kinase inhibitors TKI
2024-11-11

In this scenario, the receptor tyrosine kinase inhibitors (TKI), sunitinib, an anti-angiogenic agent, was tested in phase III trial, leading to a longer progressing free survival when compared to interferon (median: 11 vs. 5mo, respectively, hazard ratio (HR) = 0.42; 95% CI: 0.32–0.54; P progression
-
br Conflicts of interest br Financial support This work was
2024-11-11

Conflicts of interest Financial support This work was supported by grants from the Fondazione Cariplo [Grant number 2011-0463] (Carini); and by Funds for Original Research of the Università del Piemonte Orientale (2016, Project: Carini-Boldorini). The sponsors had no involvement in study desig
16408 records 78/1094 page Previous Next First page 上5页 7677787980 下5页 Last page